We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bio-Rad Launches SARS-CoV-2 Variant RT-PCR Assays
Product News

Bio-Rad Launches SARS-CoV-2 Variant RT-PCR Assays

Bio-Rad Launches SARS-CoV-2 Variant RT-PCR Assays
Product News

Bio-Rad Launches SARS-CoV-2 Variant RT-PCR Assays

Credit: Belova59/ Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bio-Rad Launches SARS-CoV-2 Variant RT-PCR Assays"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, has announced the launch of the SARS-CoV-2 Variant RT-PCR Assays for research use only (RUO). The assays can detect SARS-CoV-2 (the virus associated with COVID-19) variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations in SARS-CoV-2 using reverse transcription PCR (RT-PCR) often prior to a next generation sequencing (NGS) workflow for confirmation.

With the emergence of several SARS-CoV-2 variants of concern, public health researchers are looking for a quicker way to track the spread of these variants in a population. Laboratories that use NGS to track COVID-19 variants can detect these mutations more quickly and cost-effectively with the SARS-CoV-2 Variant RT-PCR Assays to more rapidly prioritize which samples to submit for NGS.

“We are pleased to introduce our SARS-CoV-2 Variant RT-PCR Assays to enable detection of mutations in these new variants more quickly and cost-effectively by laboratories using NGS to track COVID-19 variants,” said John Randall, Bio-Rad Vice President Marketing, Life Science Group. “The assays join Bio-Rad’s offering of research and testing products that are helping in the fight against COVID-19,” he said. 


Advertisement